Hydroxyurea

Active ingredient: Hydroxyurea

In short: Hydroxyurea tablets are indicated to reduce the frequency of painful crises and to reduce the need for blood transfusions in adult and pediatric patients, 2 years of age and older, with sickle cell anemia with recurrent moderate to severe painful crises.

Forms & strengthsTablets: 100 mg tablets: off-white, capsule-shaped, film coated, functionally scored tablet with scoring on both sides which can be divided into two equal parts, each part is debossed with “E” on one side. …
LabelANI Pharmaceuticals, Inc.
Label updatedNov 11, 2026

What is Hydroxyurea used for?

Hydroxyurea tablets are indicated to reduce the frequency of painful crises and to reduce the need for blood transfusions in adult and pediatric patients, 2 years of age and older, with sickle cell anemia with recurrent moderate to severe painful crises.

âš  Boxed warning (FDA's strongest warning)

Myelosuppression:

Hydroxyurea tablets may cause severe myelosuppression. Monitor blood counts at baseline and throughout treatment. Interrupt treatment and reduce dose as necessary .

Malignancies: Hydroxyurea is carcinogenic. Advise sun protection and monitor patients for malignancies .

Hydroxyurea dosage

The recommended hydroxyurea tablets dosing is described in Table 1.

Table 1: Dosing Recommendation Based on Blood Count

Dosing Regimen | Dose | Dose Modification Criteria | Monitoring Parameters

Initial Recommended Dosing | Adults: 15 mg/kgPediatrics: 20 mg/kgonce daily based on patient’s actual or ideal weight, whichever is less. | Monitor the patient’s blood count every 2 weeks .

Dosing Adjustment Based on Blood Counts in an acceptable range | Increase dose 5 mg/kg/day every 8 weeks or if a painful crisis occurs.Give until mild myelosuppression (absolute neutrophil count 2,000/uL to 4,000/uL) is achieved, up to a maximum of 35 mg/kg/day. | Increase dosing only if blood counts are in an acceptable range.Increase dosing if a painful crisis occurs.Do not increase if myelosuppression occurs. | Blood Counts Acceptable Range:

neutrophils greater than or equal to 2,000 cells/mm3

platelets greater than or equal to 80,000/mm3

hemoglobin greater than 5.3 g/dL

reticulocytes greater than or equal to 80,000/mm3 if the hemoglobin concentration less than 9 g/dL

Dosing Adjustment Based on Blood Counts in a toxic range | Discontinue treatment. | If blood counts are considered toxic, discontinue hydroxyurea tablets until hematologic recovery. | Blood Counts Toxic Range:

neutrophils less than 2,000 cells/mm3 younger patients with lower baseline counts may safely tolerate absolute neutrophil counts down to 1,250/mm3.

platelets less than 80,000/mm3

hemoglobin less than 4.5 g/dL

reticulocytes less than 80,000/mm3 if the hemoglobin concentration less than 9 g/dL

Dosing After Hematologic Recovery | Reduce dose by 5 mg/kg/day. | Reduce the dose from the dose associated with hematologic toxicity. May titrate up or down every 8 weeks in 5 mg/kg/day increments. The patient should be at a stable dose with no hematologic toxicity for 24 weeks. Discontinue the treatment permanently if a patient develops hematologic toxicity twice.

Hydroxyurea tablets are available in 100 mg and 1,000 mg tablets. The 100 mg tablets have 1 score line and can be split into 2 parts (each 50 mg). The 1,000 mg tablets have 3 score lines and can be split into 4 parts (each 250 mg). Therefore, the two strengths can be used to deliver doses of 1,000 mg, 750 mg, 500 mg, 250 mg, 100 mg, 50 mg and combinations thereof. Calculate the rounded doses to the nearest 50 mg or 100 mg strength based on clinical judgment.

Patients must be able to follow directions regarding drug administration and their monitoring and care.

Fetal hemoglobin (HbF) levels may be used to evaluate the efficacy of hydroxyurea tablets in clinical use. Obtain HbF levels every three to four months. Monitor for an increase in HbF of at least two-fold over the baseline value. …

How to take Hydroxyurea — instructions & advice from the label

Advise the patient or caregiver to read the FDA-approved patient labeling (Instructions for Use and Medication Guide).

There is a risk of myelosuppression. Emphasize the importance of monitoring blood counts every two weeks throughout the duration of therapy to patients taking hydroxyurea tablets . Advise patients to report signs and symptoms of infection or bleeding immediately.

Advise patients that there is a risk of cutaneous vasculitic toxicities and secondary malignancies including leukemia. Advise use of sun protection .

Advise females of reproductive potential of the potential risk to a fetus should they become pregnant while taking hydroxyurea tablets. Advise patients to inform their healthcare provider of a known or suspected pregnancy. Advise females and males of reproductive potential to use contraception during and after treatment with hydroxyurea tablets .

Advise females to discontinue breastfeeding during treatment with hydroxyurea tablets .

Advise male patients of potential risk to fertility .

Advise patients with HIV infection to contact their physician for signs and symptoms of pancreatitis, hepatic events, and peripheral neuropathy . …

Warnings & precautions

Do not take this medicine if: Hydroxyurea tablets are contraindicated in:

Patients who have demonstrated a previous hypersensitivity to hydroxyurea or any other component of its formulation .

Hydroxyurea causes severe myelosuppression. Do not initiate treatment with hydroxyurea in patients if bone marrow function is markedly depressed. Bone marrow suppression may occur, and leukopenia is generally its first and most common manifestation. Thrombocytopenia and anemia occur less often, and are seldom seen without a preceding leukopenia.

Some patients, treated at the recommended initial dose of 15 mg/kg/day in adults or 20 mg/kg/day in children, have experienced severe or life-threatening myelosuppression. Due to the change in body weight requiring modification of daily dose, pediatric patients have an increased risk of myelosuppression at the time of dose adjustment.

Evaluate hematologic status prior to and every two weeks during treatment with hydroxyurea tablets. Provide supportive care and modify dose or discontinue hydroxyurea tablets as needed. Recovery from myelosuppression is usually observed within 15 days when therapy is interrupted. Resume therapy after interruption at a lower dose .

Hydroxyurea is a human carcinogen. In patients receiving long-term hydroxyurea for myeloproliferative disorders (a condition for which hydroxyurea tablets are not approved), secondary leukemia has been reported.

Leukemia secondary to long-term hydroxyurea has also been reported in patients with for sickle cell disease. Leukemia has also been reported in patients with sickle cell disease and no prior history of treatment with hydroxyurea.

Skin cancer has also been reported in patients receiving long-term hydroxyurea. Advise protection from sun exposure and monitor for the development of secondary malignancies. …

Hydroxyurea side effects

The following clinically significant adverse reactions are described elsewhere in the labeling:

Myelosuppression

Malignancies

Vasculitic toxicities (including Leg Ulcers)

Risks with concomitant use of antiretroviral drugs

Risk with concomitant use of live virus vaccine

Macrocytosis

Hemolytic Anemia

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety of hydroxyurea tablets has been assessed in 405 pediatric patients with sickle cell disease from 2-18 years of age and 1077 adults in the European Sickle Cell Disease prospective Cohort study ESCORT-HU.

The most frequently reported adverse reactions in ESCORT-HU were infections and myelosuppression, with mild to moderate neutropenia as the most common manifestation.

Other adverse reactions include skin and subcutaneous disorders (skin depigmentation/melanonychia, skin rash, alopecia), gastrointestinal disorders, vitamin D deficiency and headache.

At least one serious adverse reaction was reported in 33% of the 405 pediatric patients and 32% of the 1077 adults with sickle cell disease in ESCORT-HU. The most frequent serious adverse reactions were infections (18%), and blood and lymphatic system disorders (9%) in children, including serious neutropenia (3.2%), thrombocytopenia (3%) and anemia (3%). …

Drug interactions

Pancreatitis

Pancreatitis (including fatal cases) have occurred in patients with HIV infection during therapy with hydroxyurea and didanosine, with or without stavudine. Hydroxyurea is not indicated for the treatment of HIV infection; however, if patients with HIV infection are treated with hydroxyurea, and in particular, in combination with didanosine and/or stavudine, monitor closely for signs and symptoms of pancreatitis. Permanently discontinue therapy with hydroxyurea in patients who develop signs and symptoms of pancreatitis.

Hepatotoxicity

Hepatotoxicity and hepatic failure resulting in death have been reported during postmarketing surveillance in patients with HIV infection treated with hydroxyurea and other antiretroviral drugs. Fatal hepatic events were reported most often in patients treated with the combination of hydroxyurea, didanosine, and stavudine. Avoid this combination.

Peripheral Neuropathy

Peripheral neuropathy, which was severe in some cases, has been reported in patients with HIV infection receiving hydroxyurea in combination with antiretroviral drugs, including didanosine, with or without stavudine. …

About this medicine

Hydroxyurea tablets is an antimetabolite that is available for oral use as functionally scored 100 mg film-coated tablet and functionally triple-scored 1,000 mg film-coated tablet containing 100 and 1,000 mg of hydroxyurea, respectively. Inactive ingredients include microcrystalline cellulose, colloidal silicon dioxide, sodium stearyl fumarate, film-coating agent amino methacrylate copolymer.

Hydroxyurea is a white crystalline powder. It has a molecular weight of 76.05. Its structural formula is:

How it works: The precise mechanism by which hydroxyurea produces its cytotoxic and cytoreductive effects is not known. However, various studies support the hypothesis that hydroxyurea causes an immediate inhibition of DNA synthesis by acting as a ribonucleotide reductase inhibitor, without interfering with the synthesis of ribonucleic acid or of protein. The mechanisms by which hydroxyurea produces its beneficial effects in patients with sickle cell Anemia (SCA) are uncertain.

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID f7b8cae7-7f38-4c17-a9e2-fc123c102e0c. Read the full official label on DailyMed.

Related medicines

Gabapentin Meloxicam Acetaminophen and Hydrocodone Duloxetine Prednisone Ibuprofen Tramadol Cyclobenzaprine